Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment (EPILOGUE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04343339
Recruitment Status : Completed
First Posted : April 13, 2020
Last Update Posted : October 8, 2020
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:

The current containment linked to COVID-19 will have consequences for people suffering from addiction and there is a risk of overdoses when the containment ends. So the investigators hypothesize that this health crisis is an opportunity to develop risk reduction and access to care for vulnerable people who lives with an addiction.

The main objective of this study is to describe the changes in the psychoactive substances consumption during the containment in people suffering from addiction. The secondary objectives are to describe the evolution at 1 month from the end of the containment of problematic consumption and the level of access to care of these users


Condition or disease
Addiction, Substance COVID-19

Layout table for study information
Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment - EPILOGUE
Actual Study Start Date : April 8, 2020
Actual Primary Completion Date : July 30, 2020
Actual Study Completion Date : September 30, 2020



Primary Outcome Measures :
  1. Evolution of consumption [ Time Frame: 1 day ]
    measurement of the difference in drugs consumption caused by containment (delta)

  2. Evolution of consumption [ Time Frame: 1 month after confinmant ]
    measurement of the difference in drugs consumption caused by containment (delta)


Secondary Outcome Measures :
  1. health care access [ Time Frame: 1 day ]
    number of drug users referred to care (%)

  2. health care access [ Time Frame: 1 month after confinmant ]
    number of drug users referred to care (%)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Person who lives with an addiction accepting the principle of the study
Criteria

Inclusion criteria:

  • >18 years
  • Accept study
  • live with an addiction

Exclusion criteria:

- not being able to answer the questionnaire


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04343339


Locations
Layout table for location information
France
Uhmontpellier
Montpellier, France, 34295
Sponsors and Collaborators
University Hospital, Montpellier
Investigators
Layout table for investigator information
Study Director: Hélène Donnadieu-Rigole, MD PhD University Hospital, Montpellier
Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT04343339    
Other Study ID Numbers: RECHMPL20_0195
First Posted: April 13, 2020    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: NC

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Montpellier:
Risk of overdose on de-confinment
COVID-19 containment will change drugs practices
COVID-19 containment will changes access to care
Addiction is a common disease
Alcohol
Containment
Drug use
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Behavior, Addictive
Compulsive Behavior
Impulsive Behavior
Chemically-Induced Disorders
Mental Disorders